Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.46 |
| ▸ | ACACB | O00763 | 3/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27679978 | 0.91 | THRA (0.45) | THRATHRBACACBFFAR4 | |
| SCHEMBL13563905 | 0.86 | THRA (0.41) | THRATHRBP4HTMFFAR1ACACB | |
| Hydrochloric Acid SCHEMBL3403722 | 0.85 | THRA (0.41) | THRATHRBP4HTMFFAR1ACACB | |
| SCHEMBL3685412 | 0.84 | CYP4F2 (0.47) | THRATHRBFFAR1ACACB | |
| SCHEMBL3059752 | 0.79 | THRA (0.61) | THRATHRBFFAR1FFAR4ITGB3 | |
| SCHEMBL3064902 | 0.77 | PARP15 (0.57) | THRATHRBFFAR1FFAR4ITGB3 | |
| SCHEMBL4681119 | 0.76 | MAPT (0.56) | ACHEPARP15PARP10 | |
| SCHEMBL5750878 | 0.75 | THRA (0.67) | THRATHRBP4HTMFFAR1FFAR4 | |
| SCHEMBL6069860 | 0.75 | P4HTM (0.58) | P4HTMFFAR1FFAR4LMNA | |
| SCHEMBL29886594 | 0.75 | P4HTM (0.58) | P4HTMFFAR1FFAR4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | THRA 309/4885THRB 578/4885P4HTM 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.